Seton Hall University

eRepository @ Seton Hall
Physics Publications

Department of Physics

2011

Modeling the Effects of a Simple Immune System
and Immunodeficiency on the Dynamics of
Conjointly Growing Tumor and Normal Cells
Mitra Shojania-Feizabadi
Seton Hall University

Tarynn M. Witten
Virginia Commonwealth University

Follow this and additional works at: https://scholarship.shu.edu/physics-publications
Recommended Citation
Feizabadi MS, Witten TM. Modeling the Effects of a Simple Immune System and Immunodeficiency on the Dynamics of Conjointly
Growing Tumor and Normal Cells. Int J Biol Sci 2011; 7(6):700-707. Available from http://www.biolsci.org/v07p0700.htm

Int. J. Biol. Sci. 2011, 7

Ivyspring
International Publisher

700

International Journal of Biological Sciences

Research Paper

2011; 7(6):700-707

Modeling the Effects of a Simple Immune System and Immunodeficiency on
the Dynamics of Conjointly Growing Tumor and Normal Cells
Mitra Shojania Feizabadi1 , Tarynn M. Witten2
1. Physics Department, Seton Hall University, South Orange, NJ 07079, USA
2. Center for the Study of Biological Complexity, PO Box 842030, Virginia Commonwealth University, Richmond, VA
23284-2030, USA
 Corresponding author: Mitra Shojania Feizabadi, Physics Department, Seton Hall University, 400 South Orange Ave,
South Orange, NJ 07079, Phone: 973-761-9403, Email: shojanmi@shu.edu
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2011.02.21; Accepted: 2011.05.24; Published: 2011.06.01

Abstract
In this paper, we develop a theoretical contribution towards the understanding of the
complex behavior of conjoint tumor-normal cell growth under the influence of
immuno-chemotheraputic agents under simple immune system response. In particular,
we consider a core model for the interaction of tumor cells with the surrounding normal
cells. We then add the effects of a simple immune system, and both immune-suppression
factors and immuno-chemotherapeutic agents as well. Through a series of numerical
simulations, we illustrate that the interdependency of tumor-normal cells, together with
choice of drug and the nature of the immunodeficiency, leads to a variety of interesting
patterns in the evolution of both the tumor and the normal cell populations.
Key words: Aging, tumor cell dynamics, normal cell dynamics, tumor-normal cell interactions,
chemotherapy, Immune system, Immunotherapy, Immunodeficiency

Introduction
Every day, clinical and experimental studies
provide evidence of new features that can influence
cancer dynamics and its treatment methodologies
[1-4]. Ongoing research efforts aim to provide a
clearer picture of the evolution of the tumor and
normal cells with the objective of improving cancer
treatment protocols.
During cancer progression, tumor cells interact
with the surrounding environmental components
such as normal cells, immune cells or therapeutic
agents that have been externally added to the system.
The nature of the tumor-environment interaction is
complex and depends upon many factors such as host
age, sex, and many more. They are all key factors that
can lead to complex patterns of tumor cell evolution.
Considering the tumor-environment interaction,
it has already been demonstrated that the growth of

normal and tumor cells are co-dependent due to their
biochemical and biomechanical interactions [5-12].
Additionally, researchers have experimentally explored the interaction of tumor cells with the host
immune system and the suppressive effects of the
immune cells in tumor progression [13-18]. Experimental evidence demonstrates that there is an alteration of the level of immune components during the
various stages of cancer growth. This underlines the
key role of the immune system in cancer dynamics [1,
19]. Understanding the intrinsic growth of tumor
cells, together with the interaction with their surroundings, has led to several single and multi-therapeutic strategies to modulate and control the
growth of these cells.
We can, however, examine the evolution of tumor and normal cells and complexity of the system
http://www.biolsci.org
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through the use of computational and mathematical
modeling and simulation. For example, the interaction of tumor cells with surrounding normal cells was
first mathematically introduced by Witten [20-23]. The
interaction of immune system and different therapeutic agents with tumor cells has been theoretically
modeled and studied by several research groups
[24-30].
In this paper, we make use of Witten’s [23] core
tumor-normal cell model. However, we modify it as
follows. First, we model the interaction of the immune
system with the conjointly growing tumor-normal
cells. Then, we assume a deficiency in the immune
system due to the presence of immune-suppressing
factors such as viruses. Additionally, we add a different therapeutic approach to this modified model.
We then investigate the evolution of normal and tumor cells through a series of computational simulations. Finally, we offer subsequent biological interpretations of the simulation results.

Building the Mathematical Model
Introducing the Conjoint Core Model
In the core model, both the normal and tumor
cells independently increase according to a logistic
growth law (other types of independent growth
model may be used). The interaction of tumor with
normal and normal with tumor cells is described by
the second term in the model where the normal cells
are denoted by N and the tumor cells are denoted by
T. Thus, the original core model [20-23] expresses one

701
possible dynamics for the interplay of normal and
tumor cells and it is given by the following system of
equations:

where T, N, KT, KN, rT, rN are the total number of tumor
cells, the total number of normal cells, the carrying
capacity of the tumor cells, the carrying capacity for
the normal cells, and the per capita growth rate for the
tumor and normal cells respectively and κ is the tumor-normal cell coupling constant. The second terms
in
each
equation
represent
the
normal-tumor/tumor-normal cell interactions. Here, β
has the units of 1/time (where time is measured in
arbitrary units depending upon the timescale of interest in the problem) and ρ0 is measured in units of
cells. T* is the critical number of tumor cells and as T
exceeds the critical size T*, the tumor cells increase
their ability to inhibit normal cell growth. This behavior is illustrated in Figure 1. Figure 1A, shows the
independent growth of the normal and tumor cells
(no interactions). However, in the conjoint growth
illustrated in Figure 1 B, we can see the dependency
between the cell populations. As the size of the tumor
cell population, T, exceed the critical size, T*, the size
of the normal cell population, N, begins to decrease.

Figure 1: Green curve: Evolution of normal cell population. Red curve: Evolution of tumor cells. Simulation parameters: r N=0.4, r T =0.3, K T=1.2. 106, K N=106. A: There is no interaction between normal cells and tumor cells (both
populations undergo logistic growth), κ=0, β=0. B: Normal and tumor cells are allowed to interact with each other, κ
=0.028, β =1, ρ0=1, ρ1=1000, T*=3.105, N0=1, T0=1. As the size of the tumor cells T exceed the critical size, T* (dashed
line), the size of normal cells N starts decreasing.

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7

Immune-Tumor interaction
Panetta & Kirschner mathematically modeled
the interaction of tumor cells with the immune system
and immune-therapeutic agents [31, 32]. This model,
which has been used in other studies [33, 34], explained clearly the equilibrium of the tumor-immune
system as well as the oscillatory behavior of the tumor
size around the equilibrium. In this paper, we add the
concepts of the interaction of the immune system established by Panetta and Kirschner to our conjoint
growth model. As explained in Kirschner’s model,
two variables are considered to be the main immune
system components: the first is activated immune-system cells (effector cells) including T cells and
other immune cells that are cytotoxic to tumor cells.
E(t) represents the effector cells in the modified model
equations below. The second immune system component is the concentration of IL-2, which is the main
cytokine responsible for T cells activation, growth and
differentiation at the tumor site. This variable is expressed by I(t).
The loss of tumor cells, due to the immune-effector cells can be characterized with a
Michaelis-Menten interaction term, aET/(g2 + T). Here,
‘a’ is the rate of clearance of tumor cells as a result of
these two populations and g2 is the half-saturation for
cancer clearance. Also, the activation happens because
of the presence of IL-2 hormones and is given by the
term p1EI/(g1+ I). This is also a Michaelis-Menten term.
Here p1 is the proliferation rate of immune cells and g1
is the half-saturation for the proliferation term. To
express the natural death of effector cells, the term
-µ3E is added. In this term µ2 is the death rate of the
immune cells. The change in concentration of IL-2 is
expressed as: p2TE/(g3 + T), which is the activation due
to the presence of the tumor. In this term, p2 is the
production rate of the effector molecules and g3 is the
half-saturation of production. Finally, -µ2I, is the natural loss of IL-2 by the rate of µ2.
Adding Chemo/Immuno-Therapy to the Immune-Tumor Interaction
Many factors can be considered to be immune
suppression factors, including immune-suppression
viruses. These viruses can infect the activated immune
cells. As a result of this infection, the population of
activated cells decreases and this leads to a weakened
immune system. In such a case, the treatment can
consist of immune boosting drugs such as Interleukin-2 (IL-2) [35]. Kirschner [36, 37] mathematically
characterized the general interaction of the Human
Immunodeficiency Virus and activated immune cells.
The presence of immune suppression factors reduces
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the efficiency of the immune system in battling tumor
cells. These same mathematical terms are, thus, added
to our model to explain a simple possible immune
deficiency [35]. Similar to the approach of Kirshner,
the production source of virus, V(t), can be introduced
as ηV/(b+V) where η is the production rate and b is the
saturated term. -µ1V expresses the natural death of
viruses at rate of µ1. The interaction between effector
cells and viruses can reduce the size of both populations with different rates. This is expressed as: - αVE
and -γVE to illustrate the interaction between virus
and effector cells. As a result of this interaction, the
immune effector cells decrease the population of viruses at rate α. Additionally, viruses infect some of the
effector cells and, therefore, the population of uninfected effector cells decreases at the rate γ.

Treatment Characterizations
To control cancer progression, many approaches
can be implemented, among them chemotherapy,
immunotherapy or some combination of the two. The
enhancement of the immune system by immuno-therapeutic agents that directly boost the number
of T cells has a key role in the reduction of both the
number of tumor cells and viruses. Chemotherapeutic
agents can kill the tumor population in a
dose-dependent manner [38, 29]. Feizabadi and Witten [28] have investigated the effect of the chemotherapeutic agents on a conjoint system of tumor and
normal cells. However, chemotherapeutic agents are
cytotoxic not only to tumor cells, but also to normal
and activated cells as well. Clinical evidence also indicates that some of the anticancer agents can control
the replication of viruses in a dose-dependent manner. Some data supports and some discourage the use
of anticancer agents for immuno-deficient virus
treatment. On the one hand, some drugs have strong
anti-activity virus effects, but not the ability to kill
rapidly proliferating tumor cells. On the other hand,
some of the anti-proliferating drugs may not have a
positive effect on controlling viruses [39]. Consequently, it is obvious that therapeutic potential depends upon the impact and the cross-toxicity of the
drug on different components of the system.
Knowledge of these pharmacokinetic interactions can
improve the future architecture of both drugs and
treatment strategies.
Gardner [40], first suggested the general term
aφ(1-e- ξMC)φ for φ = T, N, E as a means of describing as
drug interaction term. In our model, we have considered cellular interaction with chemotherapeutic
agents and we have allowed them to have some degree of toxicity to T, N, and E cells. Additionally, the
immunotherapeutic agent is described by the term
http://www.biolsci.org
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aEE(1-e ξMI) and it acts as an immune-boosting agent. In
the interaction terms, the constants MC and MI represent the chemotherapy and immunotherapy drug
concentrations and ξ is linked to the drug pharmacokinetics and is assumed to have the value ξ = 1 in this
preliminary study [28, 29].

ODE Model: Mathematical Construction of the
Modified Model
Combining all of the aforementioned interaction
terms, the evolution of the full system can be expressed as follows:

The evolution of the above full system is discussed in the following sections.

tion for each parameter along with the associated parameter values is given in Table 1. However, given the
generality of the model, alternate parameter values
may also be implemented allowing the user to further
investigate the kinetics of the various system components.

Model Simulation
Simulation of the compartmental evolution was
carried out using Mathematica V7.0. Our choice of
parameters is based on values previously introduced
or obtained from references in the literature. The citaTable 1: Simulation Parameters
Parameter

Units

Description

Estimated Value

Reference Source

rT
KT
β
ρ0
ρ1
a
g2
rN
KN
κ
T*
c
µ2
p1
g1
p2
g3
µ3
µ1
b
α
η
γ


Time
Cells
Time-1
Cells
Cells
Time-1
Cells
Time-1
Cells
Time-1
Cells
Time-1
Time-1
Time-1
Cells
Time-1
Cells
Time-1
Time-1
Viruses
Time-1
Time-1
Time-1
Concentration-1

Growth rate for the tumor cells
Carrying capacity of tumor cells
Normal-tumor cell interaction rate
Interaction clearance term
Half-saturation for interaction
Cancer clearance term
Half-saturation for cancer clearance
Growth rate for the normal cells
Carrying capacity of normal cells
Tumor-normal cell interaction rate
Critical size of tumor
Antigenicity
Death rate of immune cells
Proliferation rate of immune cells
Half-saturation proliferation term
Production rate of effector molecules
Half-saturation of production
Half-life of effector molecules
Death rate of viruses
Half-saturation of virus population
Effector cell-virus interaction rate
Production rate of viruses
Virus-effector cell interaction rate
Pharmacokinetic parameter

0.3
1.2*106
01
1
1000
1
105
0.4
106
0-0.028
3*105
0.005
0.03
0.1245
2*107
5
30
10
0.03
5
2.5*10-4
3*104
0.005
1

[28]
[28]
[28]
[28]
[28]
[31]
[31]
[28]
[28]
[28]
[28]
[31]
[31]
[31]
[31]
[31]
[31]
[31]
[29]

-1
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Figure 2: A: Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2
Concentration. The common parameters are the same amount as Figure 1. The new parameters are: a=1, g2=105,
c=0.005, µ2=0.03, p1=0.1245, g1=2*107, p2=5, g3=30, µ3=10. In this figure, Red curve represents the interaction with
the immune system. The Black curve represents the interaction of the system with just chemotherapeutic agents
when aT[1-exp(-MC)]=0.05, and aN[1-exp(-MC))=aE[1-exp(-MC)]=0.01. The Orange curve represents the interaction with the
chemotherapeutic agent when the killing effect of the chemotherapeutic agents on effector and normal cells is
minimum. In this case, aT[1-exp(-MC)]=0.05 and aN[1-exp(-MC)]=aE[1-exp(-MC)]=0.001. The Blue curve represents the
interaction of the system with the chemotherapeutic agents with the same parameters as the orange graph and the
immune boosting agents where aEE[1-exp(-MI)]=0.002. The Green curve represents the same case as the blue case with
higher dosage of the immune boosting drugs, aEE[1-exp(-MI)]=0.004. As explained in the text, the most effective
therapy is the case associated to the implementation of the chemotherapeutic agents that majorly kill tumor cells
together with effector cells boosting drugs. Some oscillatory behavior can be seen though around the equilibrium
when both agents are implemented before reaching the final equilibrium.

The behavior of tumor, normal, effector cells and
IL-2 concentration in a conjoint model is studied using
different simulation assumptions. In Figure 2, the
behavior of the components of the system is illustrated for the case where the system of tumor-normal
cells interacts with the host immune system components.
As the system of tumor and normal cells interacts with the immune cells, the amount of effector
cells and the concentration of IL-2 are increased due to
the presence of the tumor cells, Figure 2C and 2D. As
a result of the cancer clearance effect of the effector
cells, the population of the tumor cells decreases and

the population of the normal cells increases as compared with the dynamics illustrated in Figures 2A, 2B.
Chemotherapeutic agents are introduced into the
system of tumor-normal cells that are already interacting with the immune system and the evolution of
the system components changes. We first consider the
case in which the chemotherapeutic agent kills tumor
cells. These agents are also assumed to kill normal and
immune cells due to their toxicity. However, it is assumed that the killing rate of the chemotherapeutic
agent is higher for the tumor cells than for the normal
and the effector cells. Therefore, we observe a slight
decrease in the size of the tumor cell population. As

http://www.biolsci.org
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the size of the tumor cell population decreases, the
population of the effector cells and the IL-2 levels decrease as well. The Figure 2 black curves illustrate the
chemotherapeutic interaction.
Ideal chemotherapeutic agents (Orange curves in
Figure 2) are agents that are capable of killing significant numbers of tumor cells with very minimal effects on the normal and the effector cell populations.
In this case, the shrinkage of tumor cells is significant.
The population of the tumor cells decreases and both
the tumor cells and normal cells experience oscillations around their equilibrium during the chemotherapeutic interaction. If we then add additional
immunotherapeutic agents, the final population of
tumor cells decreases significantly. However, the interaction of the tumor cell population with immuno-chemotherapeutic agents exhibits an increased
amplitude of the oscillation before reaching a steady
state behavior (Blue and Green curves in Figure 2).
This shrinkage is combined by an oscillatory
behavior with small amplitude in oscillation. The
system expresses a better response in terms of a reduction in the size of the tumor cells, when in the
presence of chemotherapeutic agents, and the immunotherapy is added. In the current case, the final
size of the tumor cell populations is significantly
smaller. However, the more effective immunotherapeutic agents cause oscillations with larger amplitude
before reaching to a steady state behavior.
In our final case, we consider the scenario in
which the immune system has reduced effectiveness.
In this particular case, we assume that the reduction is
due to a viral load. Due to the existence of an immune-suppressant, the population of the effector cells
at the steady state decreases (Figure 3D) and, subsequently, the population of the tumor cells increases
(Figure 3A). Also, in the immune-deficient system, the
growth of the effector cells demonstrates a delayed
onset as compared to the system with no deficiency.
Additionally, we observe that the growth of effector
cells is slower in the presence of this deficiency. In the
absence of any immune deficiency, we simulated the
behavior of the tumor cells under an immune-chemotherapeutic agent. As discussed above,
under the effect of the immuno-chemotherapeutic
drugs, the population of effector cells decreases, while
there is an oscillatory behavior before reaching the
steady state. In the presence of an immune system
deficiency, in order to reach a nearly equivalent
steady state after therapy, we first used the same
amount of chemotherapy and increased the immunotherapeutic agent. We observe that a much larger
amount of this same agent is needed in order for the
system to approach the same steady state (Figure

705
3-Green). Alternatively, in order to reach the same
steady state, in the presence of any limitation in the
dosage of the immuno-therapeutic agent, one can
slightly increase the amount of immuno-therapeutic
agent together with a simultaneous increase in the
amount
chemotherapeutic
agent
(Figure
3,
Dashed-Green).

Closing Remarks
In this work, we modified Witten’s [23] conjoint
normal-tumor cell model in order to incorporate the
presence of a simple immune system. The evolution of
the system variables was investigated via computer
simulation. Various cases were considered. We first
considered the effect of a chemotherapeutic agent on
the system. We investigated different therapeutic approaches to control the size of the tumor cell population. We then considered the possibility of the existence of a virally induced deficiency in the immune
system function. In this scenario, the deficiency directly affected the behavior of tumor and normal cells
as well as the immune system components. Among
the possibilities, chemotherapeutic together with
immunotherapeutic agents demonstrated the best
outcome in terms of reducing the size of the tumor in
the absence of any deficiency. In the presence of immune deficiency factors, even the most successful
therapeutic agents needed to be re-evaluated to obtain
similar outcomes in terms of the reduction in size of
the tumor cells, as compared to a properly functioning
immune system in the absence of any deficiency.
Simulations demonstrated that either the level of
immunotherapeutic agents should significantly increase or the level of chemotherapeutic together with
immunotherapeutic agents should increase. This increase may control the size of the tumor cell population, but the toxicity of chemotherapy reduces the
immune system and the ability to battle the virus,
which may subsequently lead to death as a result of
infection.
In an attempt to control the size of the tumor cell
population, through different therapeutic protocols, it
is necessary to first evaluate any factors, which may
suppress the functionality of the immune system. Second, the nature of the therapeutic agents and the way
that they interact with normal, tumor, immune cells
and immunodeficiency factors needs to be investigated prior to implementation. In short, more information regarding the intrinsic interaction among different types of cells together with the interaction of
each group of cells and externally added agents can
lead to selecting a better treatment approach and
reaching a better outcome in the reduction and control
of the cancer.
http://www.biolsci.org
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Figure 3: In this figure the system behavior under the influence of immunodeficiency viruses is investigated. A:
Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2 Concentration. E: Evolution of Virus. Same common parameters are implemented as before. The specific parameters are
η=3*104, b=5, γ=0.005, α=2.5*10-4, µ1 =0.03. The Red curve represents the behavior of the components in the
presence of the virus. Black: General chemotherapy is then introduced and then improved to the chemotherapeutic
agents with major killing effects on tumor cells. Blue: the effector boosting drugs is added. Green: the dosage of the
immune boosting drugs is significantly increases aEE[1-exp(-MI)]=0.02 to almost reach to the equilibrium of the system
in the absence of any viruses. In dashed-Green line, instead of significantly increasing the dosage of immune boosting
drugs to reach to the equilibrium discussed in Figure 2, both chemotherapeutic and immunotherapeutic drugs was
increased, aEE[1-exp(-MI)]=0.01, aT[1-exp(-MC)]=0.05.
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